Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study

Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study

BackgroundMicrosatellite stable (MSS) colorectal cancer (CRC) has been referred to as the “cold tumor” because of almost no response to anti–programmed death-1 (PD-1) antibody. A recent REGONIVO trial showed that regorafenib plus nivolumab had an encouraging efficacy in MSS metastatic CRC (mCRC). Ho...

Full description

Bibliographic Details
Main Authors: Xuan Dai, Wenjun Ding, Yongshan He, Shiyong Huang, Yun Liu, Tingyu Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
immune checkpoint inhibitor
microsatellite stable
regorafenib
ErbB
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1227644/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1227644/full

Similar Items